Grant opportunity · PAR-25-070
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
Who can apply (as listed)
- Nonprofits with 501(c)(3) status (other than institutions of higher education)
- State governments
- Nonprofits without 501(c)(3) status (other than institutions of higher education)
- City or township governments
- County governments
- Others (see the opportunity text)
- Native American tribal governments (federally recognized)
- Native American tribal organizations (other than federally recognized governments)
- Small businesses
- Special district governments
- Private institutions of higher education
- Public and state-controlled institutions of higher education
- Independent school districts
- For-profit organizations (other than small businesses)
- Public housing authorities / Indian housing authorities
The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes. The data thus far suggests that these agents may increase the risk of some, while decreasing the risk of other obesity related cancers.
Excerpt as published. The full synopsis, required forms, and any amendments are on the official listing.
GrantSet indexes public records and is not the official application channel. Responses and applications go through Grants.gov only — the official notice there controls if anything shown here differs.